1-7 of 7
Lela M. Lucy
Close
Sort by
Journal Articles

The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS)

John F. Seymour, MBBS, PhD, Lewis R. Silverman, MD, Hartmut Döhner, Prof. MD, Pierre Fenaux, MD PhD, Ghulam J. Mufti, MD PhD, Valeria Santini, MD, Mark D. Minden, MD PhD, Richard M. Stone, MD, Lela M. Lucy, PhD, Stephen Songer, PharmD, Donna Dougherty, BSN, Randy Hinkle, RPh, MBA, Dominique Gambini, MD, C.L. Beach, PharmD, Hervé Dombret
Journal: Blood
Blood (2015) 126 (23): 3754.
https://doi.org/10.1182/blood.V126.23.3754.3754
Published: 2015
Journal Articles

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

Clinical Trials & Observations
Hervé Dombret, John F. Seymour, Aleksandra Butrym, Agnieszka Wierzbowska, Dominik Selleslag, Jun Ho Jang, Rajat Kumar, James Cavenagh, Andre C. Schuh, Anna Candoni, Christian Récher, Irwindeep Sandhu, Teresa Bernal del Castillo, Haifa Kathrin Al-Ali, Giovanni Martinelli, Jose Falantes, Richard Noppeney, Richard M. Stone, Mark D. Minden, Heidi McIntyre, Steve Songer, Lela M. Lucy, C. L. Beach, Hartmut Döhner
Journal: Blood
Blood (2015) 126 (3): 291–299.
https://doi.org/10.1182/blood-2015-01-621664
Published: 2015
Includes: Supplemental data
Journal Articles

Overall Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with >30% Bone Marrow Blasts Treated with Azacitidine By Cytogenetic Risk Status: Results of the AZA-AML-001 Study

Hartmut Döhner, MD, John F Seymour, MBBS, FRACP, PhD, Aleksandra Butrym, MD, Agnieszka Wierzbowska, MD PhD, Dominik Selleslag, MD, Jun Ho Jang, MD, James D Cavenagh, MD, Rajat Kumar, FRCPC, Andre C Schuh, MD FRCPC, Anna Candoni, MD, Christian Récher, MDPhD, Irwindeep Sandhu, MD FRCPC, Teresa Bernal del Castillo, MD, Haifa Kathrin Al-Ali, MD, Giovanni Martinelli, MD, Jose Falantes, MD, Richard M. Stone, MD, Mark D. Minden, MD PhD, Heidi McIntyre, BS, Stephen Songer, PharmD, Lela M. Lucy, MS, CL Beach, PharmD, Hervé Dombret, MD
Journal: Blood
Blood (2014) 124 (21): 621.
https://doi.org/10.1182/blood.V124.21.621.621
Published: 2014
Journal Articles

Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (>30% Bone Marrow Blasts) with Morphologic Dysplastic Changes: A Subgroup Analysis of the AZA-AML-001 Trial

John F Seymour, MBBS, FRACP, PhD, Hartmut Döhner, MD, Aleksandra Butrym, MD, Agnieszka Wierzbowska, MD PhD, Dominik Selleslag, MD, Jun Ho Jang, MD, James D Cavenagh, MD, Rajat Kumar, MD, Andre C. Schuh, MD FRCPC, Anna Candoni, MD, Christian Récher, MDPhD, Irwindeep Sandhu, MD FRCPC, Teresa Bernal del Castillo, MD, Haifa Kathrin Al-Ali, MD, Giovanni Martinelli, MD, Jose Falantes, MD, Richard M Stone, Mark D. Minden, MD PhD, Heidi McIntyre, BS, Stephen Songer, PharmD, Lela M. Lucy, MS, CL Beach, PharmD, Hervé Dombret, MD
Journal: Blood
Blood (2014) 124 (21): 10.
https://doi.org/10.1182/blood.V124.21.10.10
Published: 2014
Journal Articles

Identification of a DNA Methylation Predictive Signature of Overall Survival in Higher-Risk MDS Patients Treated with Azacitidine,

Tao Shi, PhD, Ludmila Danilova, PhD, Xiaolong Luo, PhD, Lela M. Lucy, MS, CL Beach, PharmD, Leslie Cope, PhD, James G. Herman, MD, Kyle J. MacBeth, PhD
Journal: Blood
Blood (2011) 118 (21): 3815.
https://doi.org/10.1182/blood.V118.21.3815.3815
Published: 2011
Journal Articles

Achievement of Red Blood Cell (RBC) Transfusion Independence with Azacitidine (AZA) Leads to Improved Survival In Patients with Higher-Risk Myelodysplasias Regardless of Baseline Transfusion Needs

John F Seymour, MD, FRACP, Valeria Santini, MD, Pierre Fenaux, MD, Aristoteles A.N. Giagounidis, MD, Guillermo F. Sanz, MD, PhD, Carlo Finelli, MD, Lela M. Lucy, MS, Jay Backstrom, MD, MPH, CL Beach, PharmD
Journal: Blood
Blood (2010) 116 (21): 1856.
https://doi.org/10.1182/blood.V116.21.1856.1856
Published: 2010
Journal Articles

Re-Evaluation of the Efficacy of Azacitidine (AZA) In Patients From the AZA-001 Study with Higher-Risk Myelodysplastic Syndromes (MDS) Classified by WHO Criteria and WPSS Risk

Norbert Gattermann, MD, Guillermo F. Sanz, MD, PhD, Aristoteles Giagounidis, John F Seymour, MD, FRACP, Pierre Fenaux, MD, PhD, Valeria Santini, MD, Ghulam J. Mufti, DM, FRCP, FRCPath, Petra Muus, MD, PhD, Fernando Ramos, MD, Lela M. Lucy, MS, CL Beach, PharmD, Lewis R. Silverman, MD
Journal: Blood
Blood (2010) 116 (21): 4031.
https://doi.org/10.1182/blood.V116.21.4031.4031
Published: 2010